Tefibazumab

Tefibazumab^?
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	Clumping factor A
Clinical data
Trade names	Aurexis
Identifiers
CAS Registry Number	521079-87-8^N
ATC code	None
KEGG	D06054^Y
Chemical data
Formula	C₆₅₄₈H₁₀₁₂₂N₁₇₃₀O₂₀₃₄S₄₄
Molecular mass	147.590 kDa
N (what is this?) (verify)

Tefibazumab (named Aurexis but not approved) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in a phase 2a patients with cystic fibrosis^[1] and of methicillin-resistant S. aureus.^[2]

It was developed by Inhibitex.^[3]

References

↑ Clinical trial number NCT00198289 at ClinicalTrials.gov
↑ Pan; Lorenzotti, S.; Zoncada, A. (2008). "Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection". Recent Patents on Anti-infective Drug Discovery 3 (1): 10–33. doi:10.2174/157489108783413173. PMID 18221183.
↑ John JF (2006). "Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection". Curr. Opin. Mol. Ther. 8 (5): 455–60. PMID 17078388.

Monoclonal antibodies for infectious disease and toxins

Fungal ("-fung-")

Human ("-fungu-")	Efungumab

Viral ("-vi(r)-")

Human ("-viru-")	Exbivirumab Foravirumab Libivirumab Rafivirumab Regavirumab Sevirumab Tuvirumab

Humanized ("-vizu-")	Felvizumab Motavizumab Palivizumab Suvizumab

Bacterial ("-ba(c)-")

Human ("-bacu-")	Nebacumab Panobacumab Raxibacumab

Mouse ("-baco-")	Edobacomab

Chimeric ("-baxi-")	Pagibaximab

Humanized ("-bazu-")	Tefibazumab^†

Toxin ("-tox(a)-")

Human ("-toxu-")	Actoxumab Bezlotoxumab

Humanized ("-toxazu-")	Urtoxazumab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Tefibazumab

See also

References